Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mut… Read more
Market Cap & Net Worth: Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (NASDAQ:QNCX) has a market capitalization of $5.40 Million ($5.40 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31644 globally and #10414 in its home market, demonstrating a -6.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Quince Therapeutics, Inc.'s stock price $0.10 by its total outstanding shares 55681490 (55.68 Million).
Quince Therapeutics, Inc. Market Cap History: 2019 to 2026
Quince Therapeutics, Inc.'s market capitalization history from 2019 to 2026. Data shows change from $3.13 Billion to $5.40 Million (-57.21% CAGR).
Index Memberships
Quince Therapeutics, Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #809 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2578 of 3165 |
Weight: Quince Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Quince Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Quince Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of QNCX by Market Capitalization
Companies near Quince Therapeutics, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Quince Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Quince Therapeutics, Inc. Historical Marketcap From 2019 to 2026
Between 2019 and today, Quince Therapeutics, Inc.'s market cap moved from $3.13 Billion to $ 5.40 Million, with a yearly change of -57.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.40 Million | -97.10% |
| 2025 | $186.53 Million | +79.14% |
| 2024 | $104.12 Million | +78.10% |
| 2023 | $58.47 Million | +64.84% |
| 2022 | $35.47 Million | -94.95% |
| 2021 | $702.70 Million | -54.57% |
| 2020 | $1.55 Billion | -50.52% |
| 2019 | $3.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Quince Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.40 Million USD |
| MoneyControl | $5.40 Million USD |
| MarketWatch | $5.40 Million USD |
| marketcap.company | $5.40 Million USD |
| Reuters | $5.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.